CEO Message
CEO MESSAGE
Since its founding in 2017, Addpharma has become Korea’s leading developer of Incrementally Modified Drugs (IMD) based on its advanced technology and industry’s top professionals.
Thanks to your continuous support, our company was able to achieve this accomplishment.
We greatly value our customers and dedicate our efforts to human health and well-being.
-
-
Addpharma is a company focused on research and development
Addpharma’s personnel has vast experience on successfully developing several types of IMDs, including Fixed Dose combinations (FDC), controlled-release drugs, and drugs with enhanced bioavailability. Our company has established partnerships with several leading companies in the industry, and we perform all steps of drug development based on our expertise.
-
-
Our employees are the owners of our company
We believe that corporate performance is based on the happiness of its employees. Our efforts are focused on ensuring that we have a desirable and productive working culture and a proper compensation system.
-
-
Addpharma strives to be the best
Addpharma has an extensive pipeline along with vast experience in successful IMD development. We maximize efficiency by carefully taking market value, odds of success, and profit rate into account. Addpharma will prioritize establishing partnerships with top pharmaceutical companies in Korea and show a solid presence in the global market.
